loading...| Preferred Name |
Everolimus |
|
| Synonyms |
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone 42-O-(2-Hydroxy)ethyl Rapamycin Afinitor Certican EVEROLIMUS Everolimus RAD 001 RAD-001 RAD001 Votubia Zortress everolimus |
|
| Definitions |
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C48387 |
|
| Accepted_Therapeutic_Use_For |
neuroendocrine tumors (NET) of gastrointestinal (GI), lung or pancreatic origin |
|
| ALT_DEFINITION |
A drug used to treat advanced kidney cancer that did not respond to treatment with certain other anticancer drugs. It is also being studied in the treatment of other types of cancer. Afinitor stops cancer cells from dividing and may block the growth of new blood vessels that tumors need to grow. It also decreases the body's immune responses. It is a type of immunosuppressant and a type of antiangiogenesis agent. |
|
| CAS_Registry |
159351-69-6 |
|
| Chemical_Formula |
C53H83NO14 |
|
| code |
C48387 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05) |
|
| Display_Name |
Everolimus |
|
| FDA_UNII_Code |
9HW64Q8G6G |
|
| FULL_SYN |
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone 42-O-(2-Hydroxy)ethyl Rapamycin Afinitor Certican EVEROLIMUS Everolimus RAD 001 RAD-001 RAD001 Votubia Zortress everolimus |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Everolimus |
|
| Legacy Concept Name |
Everolimus |
|
| Maps_To |
Everolimus |
|
| NCI_Drug_Dictionary_ID |
372905 |
|
| NSC Number |
733504 |
|
| PDQ_Closed_Trial_Search_ID |
372905 |
|
| PDQ_Open_Trial_Search_ID |
372905 |
|
| Preferred_Name |
Everolimus |
|
| prefixIRI |
Thesaurus:C48387 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0541315 |
|
| subClassOf |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1742 |